company background image
CYP

Cynata TherapeuticsASX:CYP Stock Report

Market Cap

AU$88.1m

7D

-1.6%

1Y

-25.7%

Updated

22 Oct, 2021

Data

Company Financials
CYP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CYP Overview

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Cynata Therapeutics
Historical stock prices
Current Share PriceAU$0.62
52 Week HighAU$0.47
52 Week LowAU$0.93
Beta0.33
1 Month Change16.98%
3 Month Change29.17%
1 Year Change-25.75%
3 Year Change-42.86%
5 Year Change-12.68%
Change since IPO-86.52%

Recent News & Updates

Aug 11
We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

CYPAU BiotechsAU Market
7D-1.6%-0.9%0.7%
1Y-25.7%2.1%21.4%

Return vs Industry: CYP underperformed the Australian Biotechs industry which returned 2.5% over the past year.

Return vs Market: CYP underperformed the Australian Market which returned 21.1% over the past year.

Price Volatility

Is CYP's price volatile compared to industry and market?
CYP volatility
CYP Beta0.33
Industry Beta1.63
Market Beta1

Stable Share Price: CYP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CYP's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011n/aRoss MacDonaldhttps://www.cynata.com

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model.

Cynata Therapeutics Fundamentals Summary

How do Cynata Therapeutics's earnings and revenue compare to its market cap?
CYP fundamental statistics
Market CapAU$88.12m
Earnings (TTM)-AU$7.69m
Revenue (TTM)AU$1.55m

57.5x

P/S Ratio

-11.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYP income statement (TTM)
RevenueAU$1.55m
Cost of RevenueAU$0
Gross ProfitAU$1.55m
ExpensesAU$9.24m
Earnings-AU$7.69m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.054
Gross Margin100.00%
Net Profit Margin-497.38%
Debt/Equity Ratio0.0%

How did CYP perform over the long term?

See historical performance and comparison

Valuation

Is Cynata Therapeutics undervalued compared to its fair value and its price relative to the market?

3.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CYP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CYP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CYP is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: CYP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYP is good value based on its PB Ratio (3.1x) compared to the AU Biotechs industry average (4.8x).


Future Growth

How is Cynata Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cynata Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Cynata Therapeutics performed over the past 5 years?

-9.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYP is currently unprofitable.

Growing Profit Margin: CYP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYP is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.

Accelerating Growth: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: CYP has a negative Return on Equity (-27.1%), as it is currently unprofitable.


Financial Health

How is Cynata Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CYP's short term assets (A$27.3M) exceed its short term liabilities (A$1.6M).

Long Term Liabilities: CYP has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CYP is debt free.

Reducing Debt: CYP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYP has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CYP has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.2% each year


Dividend

What is Cynata Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average board tenure


CEO

Ross MacDonald (63 yo)

no data

Tenure

AU$906,846

Compensation

Dr. Ross Alexander MacDonald, Ph D., Grad Dip in Bus Admin serves as the Chief Executive Officer and Managing Director at Cynata Therapeutics Limited (formerly Eco Quest Limited). Dr. MacDonald served as t...


CEO Compensation Analysis

Compensation vs Market: Ross's total compensation ($USD679.13K) is above average for companies of similar size in the Australian market ($USD303.55K).

Compensation vs Earnings: Ross's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: CYP's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.3%.


Top Shareholders

Company Information

Cynata Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Cynata Therapeutics Limited
  • Ticker: CYP
  • Exchange: ASX
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$88.115m
  • Shares outstanding: 143.28m
  • Website: https://www.cynata.com

Location

  • Cynata Therapeutics Limited
  • 100 Cubitt Street
  • Level 3
  • Cremorne
  • Victoria
  • 3121
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/22 07:04
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.